• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Horizon touts data from trials for thyroid eye disease infusion treatment

April 16, 2021 By Sean Whooley

Horizon TherapeuticsHorizon Therapeutics announced today that study results highlight the success of its Tepezza infusion for treating thyroid eye disease.

Dublin, Ireland-based Horizon’s Tepezza proved in pooled Phase 2 and Phase 3 clinical trial data that it significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a long-term response, according to a news release.

Tepezza, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor, is touted as the first and only medicine approved by the FDA for treating TED. It is delivered to patients via infusion.

Results, published in The Lancet Diabetes & Endocrinology, covered two 24-week, multicenter, double-masked, placebo-controlled clinical trials in which 84 patients were randomized to receive Tepezza and 87 received a placebo once every three weeks for a total of eight infusions.

Patients were analyzed for proptosis and diplopia and a posthoc analysis of a combined outcome measure, which calculated the percentage of patients with clinical improvement in one eye in at least two of the following: proptosis, diplopia, eyelid swelling, lid aperture, globe motility and clinical activity score.

Horizon found no evidence for acute disease rebound, observing 87% of patients responding to proptosis and 66% to diplopia, with 92% ophthalmic composite outcome observed seven weeks after the last Tepezza dose. The posthoc analysis indicated that 81% of Tepezza patients compared to 44% of placebo patients were responders at week 24.

At 51 weeks after the final dose, 67% responded to proptosis, 69% to diplopia and the composite outcome response came in at 83% .

“These comprehensive data enlighten our understanding of how Tepezza improves thyroid eye disease symptoms in both the short- and longer-term,” Horizon executive director of clinical development, ophthalmology Dr. Saba Sile said in the release. “We will apply these learnings as we continue to study Tepezza in the broader thyroid eye disease population and report findings in a larger, more diverse patient population in the future.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Horizon Therapeutics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS